Necitumumab
Summary
Risk. Exempt.
This information is taken from an assessment report.
Detailed information
Assessment report
Assessment report for Portrazza (necitumumab), 17 December 2015, EMA/CHMP/15391/2016.
"Necitumumab is a protein, which is expected to biodegrade in the environment and not be a significant risk to the environment. Thus, according to the “Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use” (EMEA/CHMP/SWP/4447/00), necitumumab is exempt from preparation of an Environmental Risk Assessment as the product and excipients do not pose a significant risk to the environment."
Fass environmental information
Environmental information is missing on fass.se (2019-09-04). It is voluntary for manufacturers to provide information about environmental impact on fass.se.
References
- European Medicines Agency. European public assessment reports (EPAR). Portrazza (necitumumab),17 December 2015, EMA/CHMP/15391/2016.
- European Medicines Agency, EMA: Committee for Medicinal Products for Human Use (CHMP). Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. 1 June 2006.
Author: Health and Medical Care Administration, Region Stockholm